Clinical trials
Non Muscle Invasive Bladder Cancer clinical trials
Below are recruiting non muscle invasive bladder cancer clinical trials, each written for real people, not researchers. We’re tracking 144 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06319820RecruitingPhase 3
TAR-210 vs standard bladder chemo for FGFR-mutated bladder cancer
This trial compares a new drug, TAR-210, which is placed directly into the bladder, against standard chemotherapy given through a catheter. It is for people with a specific type of bladder cancer that has a change in the FGFR gene.
Little Rock, ArkansasAges 18 years+ - NCT06351904RecruitingPhase 1
Testing RAG-01 for bladder cancer that returned after BCG treatment
This trial tests a new drug, RAG-01, for people with a type of bladder cancer called non-muscle-invasive bladder cancer (NMIBC) that has come back after BCG therapy. The drug is given through a catheter into the bladder, and the study aims to see if it can help control the cancer.
St Leonards, New South WalesAges 18–75 - NCT06394570RecruitingPhase 1/Phase 2
Enfortumab vedotin and radiation for bladder cancer
This trial tests a combination of a targeted drug (enfortumab vedotin) and focused radiation before surgery to remove the bladder. It is for people with muscle-invasive bladder cancer who cannot take cisplatin chemotherapy.
Dallas, TexasAges 18 years+ - NCT06396533Recruiting
Improving cancer staging before bladder removal surgery
This trial tests if adding a special CT scan before bladder removal helps find muscle-invasive bladder cancer earlier. It includes people with different stages of bladder cancer who are planning to have their bladder removed.
Omaha, NebraskaAges 18 years+ - NCT06441110RecruitingPhase 3
BCG instillation for medium- to high-risk bladder cancer
This trial tests whether a specific schedule of BCG (a weakened germ that boosts the immune system) placed directly into the bladder is safe and effective for medium- to high-risk bladder cancer that hasn't grown into the muscle. It aims to see if adjusting the standard BCG course can work better for people with a PD-L1-positive tumor.
Fuzhou, FujianAges 18–75 - NCT06470282RecruitingPhase 1/Phase 2
Drug combo plus radiation for muscle-invasive bladder cancer
This trial tests a combination of two drugs (enfortumab vedotin and pembrolizumab) plus radiation therapy for people with bladder cancer that has grown into the muscle layer. The goal is to see if this treatment can kill the cancer while avoiding the need for bladder removal surgery.
San Francisco, CaliforniaAges 18 years+ - NCT06503614RecruitingPhase 2
Durvalumab and monalizumab for early bladder cancer
This trial tests two drugs—durvalumab and monalizumab—for people with early-stage bladder cancer that hasn't spread into the muscle and has persisted or returned after BCG treatment. The goal is to see if this combination can control the cancer and delay or avoid the need for bladder removal surgery.
Tampa, FloridaAges 18 years+ - NCT06525571RecruitingPhase 3
Blue light surgery for high-risk bladder cancer
This trial tests if using blue light during surgery helps remove all cancer in people with high-risk non-muscle invasive bladder cancer. It may lower the chance of the cancer coming back.
Washington D.C., District of ColumbiaAges 18 years+ - NCT06537154RecruitingPhase 2/Phase 3
Neoadjuvant therapy for bladder cancer with active surveillance
This trial tests whether people with muscle-invasive bladder cancer can safely avoid immediate surgery or radiation after a short course of chemotherapy. Instead, they would be closely monitored and only treated if the cancer comes back.
Vancouver, British ColumbiaAges 19 years+ - NCT06551233RecruitingPhase 1
Testing a new drug for high-risk bladder cancer
This trial tests a new drug called 9MW2821 for people with high-risk bladder cancer that hasn't grown into the bladder muscle. It's for those who have already tried other treatments that didn't work or who can't have standard therapy.
Nanjing, JiangsuAges 18 years+ - NCT06567743RecruitingPhase 2
Study of a new virus therapy for high-risk bladder cancer
This trial tests a new virus-based medicine, cretostimogene grenadenorepvec, given directly into the bladder for people with high-risk non-muscle-invasive bladder cancer. It may help prevent the cancer from coming back, especially for those who have not had BCG treatment or whose cancer did not respond to BCG.
Phoenix, ArizonaAges 18 years+ - NCT06571708RecruitingPhase 2
Chemo plus immunotherapy for muscle-invasive bladder cancer
This trial tests adding two immunotherapy drugs (cemiplimab and fianlimab) to standard chemotherapy (gemcitabine and cisplatin) for people with bladder cancer that has grown into the muscle layer but hasn't spread. The goal is to see if adding these immunotherapies helps shrink the tumor before surgery.
New York, New YorkAges 18 years+ - NCT06605404Recruiting
Pan-tumor study of a blood test after cancer surgery
This study is testing a new blood test that looks for leftover cancer cells after surgery. It is for people with different types of solid tumors who are planning to have surgery to cure their cancer. The goal is to see if the test can help guide future treatment decisions.
San Diego, CaliforniaAges 18 years+ - NCT06632964RecruitingPhase 1
Testing VT-101 for non-muscle invasive bladder cancer
This study tests a new drug called VT-101 for people with a type of bladder cancer that hasn't spread into the muscle wall. The goal is to see if the drug is safe and effective. It might be an option if you have already had a biopsy and are not eligible for or refuse surgery.
Xuzhou, JiangsuAges 18–75 - NCT06663137RecruitingPhase 2
Study of a new treatment for high-grade bladder cancer
This trial tests a new treatment called NDV01 KIT for people with high-grade non-muscle invasive bladder cancer that hasn't gotten better after BCG therapy. It's for those who cannot or choose not to have their bladder removed.
RaananaAges 18–80 - NCT06682728RecruitingPhase 2
Treating high-risk bladder cancer after surgery
This trial tests a combination of two drugs (sacituzumab govitecan and nivolumab) given after surgery to prevent the return of muscle-invasive bladder cancer. It is for patients whose cancer has a high chance of coming back despite surgery.
Orange, CaliforniaAges 18 years+ - NCT06696794RecruitingPhase 3
Testing mitomycin before surgery for high-risk bladder cancer
This trial tests whether giving mitomycin directly into the bladder before surgery can help people with high-risk non-muscle-invasive bladder cancer. The goal is to see if this approach is safe and effective at preventing cancer from coming back.
Wuhan, HubeiAges 18–75 - NCT06704191RecruitingPhase 1/Phase 2
In-home chemo for bladder cancer trial
This trial tests if you can receive chemotherapy for bladder cancer at home instead of in the clinic. It is for people with early-stage bladder cancer who are already getting certain types of intravesical (inside the bladder) treatment.
Jacksonville, FloridaAges 18 years+ - NCT06637423RecruitingPhase 1/Phase 2
Study of sacituzumab tirumotecan for low-grade bladder cancer
This trial tests a new drug called sacituzumab tirumotecan for people with low-grade bladder cancer that hasn't spread into the bladder muscle. The goal is to see if it can help shrink or control the tumors.
Bakersfield, CaliforniaAges 18 years+ - NCT07302230Recruiting
Home exercise app for bladder cancer patients
This trial tests whether a home-based physical activity program using a smartphone app helps people with non-muscle invasive bladder cancer become more active compared to a health education group. It's designed for those who are not very active and want to improve their health.
Seattle, WashingtonAges 18 years+ - NCT06732531RecruitingPhase 1/Phase 2
Testing a new drug for high-risk bladder cancer that came back after BCG
This clinical trial tests a new drug, BH011, for people with high-risk, non-muscle-invasive bladder cancer that has come back or not responded to BCG therapy. The goal is to see if the drug is safe and works well when given directly into the bladder, as an alternative to bladder removal surgery.
Beijing, Beijing MunicipalityAges 18 years+ - NCT06733363RecruitingPhase 2
Vegetable diet to prevent bladder cancer return
This trial tests whether a diet rich in cruciferous vegetables (like broccoli, cauliflower, and kale) can help prevent bladder cancer from coming back or getting worse. It is for people with early-stage, non-invasive bladder cancer who live in New York State.
Buffalo, New YorkAges 18 years+ - NCT06735287Recruiting
Bladder-sparing treatment for large bladder cancer
This trial tests a combination of chemotherapy and immunotherapy to treat large, non-invasive bladder cancer before and after surgery. It aims to avoid removing the bladder while still effectively treating the cancer.
Nanjing, JiangsuAges 18–80 - NCT06781879RecruitingPhase 4
Comparing bladder medication vs surgery for returning low-grade bladder cancer
This trial tests whether a chemotherapy drug placed directly into the bladder (chemoablation) works as well as surgery followed by chemotherapy for people whose low-grade bladder tumors have come back. It aims to find a less invasive option that still controls the cancer.
AalborgAges 18 years+
Hear when a new Non Muscle Invasive Bladder Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for non muscle invasive bladder cancer?
- Yes. Clin2 currently lists 144 recruiting non muscle invasive bladder cancer studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a non muscle invasive bladder cancer trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a non muscle invasive bladder cancer trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
- High Risk Non-muscle Invasive Bladder Cancer
- Non-muscle Invasive Bladder Cancer With Carcinoma in Situ
- Muscle Invasive Bladder Cancer (MIBC)
- Non-Muscle Invasive Bladder Urothelial Carcinoma
- Non-Muscle Invasive Bladder Neoplasms
- Non-Muscle Invasive Bladder Carcinoma
- Recurrent Non-Muscle Invasive Bladder Carcinoma
- Non Small Cell Lung Cancer
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.